PHASE-II TRIAL OF CISPLATIN AND ETOPOSIDE AS FIRST-LINE THERAPY IN METASTATIC BREAST-CARCINOMA

Twenty-two patients with metastatic breast carcinoma were treated with a combination of cisplatin (100 mg/m(2) i.v. day 1) and etoposide (10 0 mg/m(2) i.v. days 1-3). Eligible patients had measurable disease wit h normal organ functions, performance status <3, age <70 years and no previous chemotherapy for metastatic disease. Twenty patients were ass essable for response. Objective responses were seen in 50% (95% confid ence limits: 24.4-67.8). One patient achieved a complete response. Obj ective response was observed in patients with visceral metastatic dise ase and who had received anthracyclin-containing regimens in previous chemotherapy. Median survival after therapy was 55 weeks. Median time to progression was 23 weeks. Hematologic toxicity was Limiting. Cispla tin plus etoposide is an active combination in advanced breast cancer.